Genmab A (GMAB) Other Accumulated Expenses (2019 - 2026)

Genmab A's Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $861.0 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 17120.0% year-over-year to $861.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $861.0 million (up 17120.0% YoY) and the FY2025 annual result came in at $1.1 billion, up 118.61% from the prior year.
• Other Accumulated Expenses was $861.0 million for Q1 2026 at Genmab A, down from $1.1 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.1 billion in Q4 2025 and bottomed at $5.0 million in Q1 2025.
• A 3-year average of $598.8 million and a median of $584.5 million in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses jumped 118.61% — and 2026, when it surged 17120.0%.
• Genmab A's Other Accumulated Expenses stood at $489.0 million in 2024, then soared by 118.61% to $1.1 billion in 2025, then slipped by 19.46% to $861.0 million in 2026.
• Business Quant data shows GMAB's Other Accumulated Expenses at $861.0 million in Q1 2026, $1.1 billion in Q4 2025, and $602.0 million in Q3 2025.